N-t-butyl-2,2-dimethylbutyramide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-t-butyl-2,2-dimethylbutyramide
• 英文别名: N-tert-butyl-2,2-dimethylbutanamide
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: ZBRRLABBHRYWNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Copolymer with phosphoryl group and molded articles of same
  申请人：Tsutsumi Osamu

  公开号：US20070141474A1

  公开（公告）日：2007-06-21

  (Problems) Providing a polymer, a composition and a molded article, which are inexpensive and have great chemical stability and high mechanical strength with no content of halogen elements and less environmental burden during disposal. (Means for Resolution) A copolymer containing at least two or more polymer segments, where at least one polymer segment contains a phosphoryl derivative represented by the following general formula (1) and at least one polymer segment never contains a phosphoryl derivative represented by the following general formula (1): (where R independently represents hydrocarbon, an aromatic ring, hydrogen, a metal ion or onium ion).

  （问题）提供一种聚合物、组合物和成型品，它们价格便宜、具有很高的化学稳定性和机械强度，没有卤素元素的含量，在处理过程中减少环境负担。（解决方案）一种共聚物，其中至少包含两个或更多的聚合物段，其中至少一个聚合物段包含以下通式（1）所代表的磷酰衍生物，而至少一个聚合物段不包含以下通式（1）所代表的磷酰衍生物：（其中R独立地表示碳氢化合物、芳香环、氢、金属离子或离子）。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20080139597A1

  公开（公告）日：2008-06-12

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了具有二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还描述了使用这种化合物、制药组合物和药物来治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理和/或症状性疾病或病况的方法。
• Pyrrolidine amide compounds as histone demethylase inhibitors
  申请人：GENENTECH, INC.

  公开号：US10022354B2

  公开（公告）日：2018-07-17

  The present invention relates to compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及可用作一种或多种组蛋白去甲基化酶（如 KDM5）抑制剂的化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物，以及使用所述组合物治疗各种疾病的方法。
• Small molecule based antibody-recruiting compounds for cancer treatment
  申请人：YALE UNIVERSITY

  公开号：US10633374B2

  公开（公告）日：2020-04-28

  The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

  本发明涉及嵌合（包括双功能）化合物、包含这些化合物的组合物以及治疗患者或受试者癌症的方法，特别是包括转移性癌症，与正常（非癌症）细胞相比，癌细胞表现出细胞表面尿激酶型纤溶酶原激活剂受体（尿激酶受体）的过度表达（表达增强）。这些化合物与癌细胞（包括转移性癌细胞）表面的尿激酶型纤溶酶原激活剂受体（uPAR）结合，从而招募患者或受试者的本地抗体，这些抗体可通过抗体依赖性细胞吞噬作用和抗体依赖性细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）选择性地降解和/或使靶向癌细胞失活，从而对抗大量和多种癌症、从而导致癌细胞死亡，抑制癌症的生长、扩散和/或转移，包括缓解和治愈患者的癌症。
• TAGGING REAGENTS AND METHODS FOR HYDROXYLATED COMPOUNDS
  申请人：Purkayastha Subhasish

  公开号：US20080014642A1

  公开（公告）日：2008-01-17

  In various aspects, the present teachings provide labeling reagents and sets of labeling reagents for the relative quantitation, absolute quantitation, or both, of hydroxylated compounds including, but not limited to, hydroxylated ring containing compounds, steroids and sterols. In various aspects, the present teachings also provide methods for the analysis hydroxylated compounds including, but not limited to, hydroxylated ring containing compounds, steroids and sterols my MS/MS methods.